Afficher la notice abrégée
| dc.creator | Bakalos G., Schreitmüller T. | en |
| dc.date.accessioned | 2023-01-31T07:35:16Z | |
| dc.date.available | 2023-01-31T07:35:16Z | |
| dc.date.issued | 2017 | |
| dc.identifier | 10.1136/esmoopen-2017-000281 | |
| dc.identifier.issn | 20597029 | |
| dc.identifier.uri | http://hdl.handle.net/11615/71057 | |
| dc.description.abstract | [No abstract available] | en |
| dc.language.iso | en | en |
| dc.source | ESMO Open | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048101352&doi=10.1136%2fesmoopen-2017-000281&partnerID=40&md5=a903ee55bceb23888c83d40893055063 | |
| dc.subject | BMJ Publishing Group | en |
| dc.title | Reply to Biosimilars: A position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers' | en |
| dc.type | other | en |
Fichier(s) constituant ce document
|
Il n'y a pas de fichiers associés à ce document.
|
Ce document figure dans la(les) collection(s) suivante(s)
Afficher la notice abrégée